Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.

L, Blonde; J, Rosenstock; Prato S, Del; R, Henry; N, Shehadeh; J, Frias; E, Niemoeller; E, Souhami; C, Ji; VR, Aroda

doi:10.2337/dc19-1357

Public

Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.

Shared by NobleBlocks on Sep 17, 2019 • 12:00 AM UTC

Authors:

Blonde L

Rosenstock J

Del Prato S

Abstract

<h4>Objective</h4>Fixed-ratio combinations of basal insulin plus glucagon-like peptide 1 receptor agonist (GLP-1 RA) allow concomitant administration of two proven complementary injectable therapies for type 2 diabetes. This study investigated switching to a titratable fixed-ratio combination of ins...

Discussions